Based in Secaucus, New Jersey, Quest Diagnostics Incorporated (DGX), with a market capitalization of approximately $25.8 billion, is a leading provider of diagnostic information services. The company offers laboratory testing and health insights that help consumers, physicians and hospitals screen, prevent, diagnose and monitor diseases, while improving access to affordable and actionable healthcare information.
DGX is set to report its Q3 earnings on Thursday, October 22, 2026, before the market opens. Ahead of the release, analysts expect the company to report diluted EPS of $2.85, up 9.6% from $2.60 in the year-ago quarter. Quest Diagnostics has also exceeded Wall Street’s EPS estimates in each of the past four quarters, highlighting its consistent earnings performance.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts expect DGX to report EPS of $11.15, up 13.2% from $9.85 in fiscal 2025. Moreover, EPS is projected to grow another 7.4% year over year to $11.97 in fiscal 2027.
www.barchart.comDGX stock has risen 28.9% over the past 52 weeks, outperforming both the S&P 500 Index ($SPX), which gained 15%, and the State Street Health Care Select Sector SPDR ETF (XLV), which advanced 16.1% over the same period.
www.barchart.comQuest Diagnostics has outperformed its peers over the past year, with the strong performance supported by robust recent earnings growth and better-than-expected financial results. On July 23, following the release of its second-quarter results, DGX shares jumped 8.6% as investors digested the report. Revenue increased 10.2% year over year to $3.04 billion, beating estimates by 2.3%, while adjusted EPS rose to $3.12, exceeding expectations by 10.5%. The company also raised its full-year adjusted EPS guidance to $11.15 at the midpoint.
More recently, on October 1, Quest Diagnostics announced strong clinical results for its Haystack MRD liquid biopsy test, demonstrating high sensitivity and 100% specificity in detecting colorectal cancer recurrence. The findings could strengthen its oncology diagnostics portfolio and further support investor sentiment.
Analysts remain cautiously bullish on DGX, with the stock carrying a consensus “Moderate Buy” rating. Among the 17 analysts covering the stock, nine recommend a “Strong Buy,” while the other eight suggest a “Hold.” Meanwhile, the average price target of $95.52 implies potential upside of 7.7% from the current share price, offering a premium to current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors. Nvidia Bull Put Spread Could Return 16% U.S. Stock Futures Muted as Europe’s Turmoil Curbs Risk Appetite; Fed Minutes Awaited As Starship Finally Reaches Orbit, Here’s How You Should Place SpaceX Stock